CT 引导下微波消融治疗乳腺癌肺转移瘤。
CT-guided microwave ablation in patients with lung metastases from breast cancer.
机构信息
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
出版信息
Thorac Cancer. 2021 Dec;12(24):3380-3386. doi: 10.1111/1759-7714.14212. Epub 2021 Nov 2.
BACKGROUND
Computed tomography (CT)-guided percutaneous microwave ablation (MWA) is a very common ablation method that shows a good local tumor control rate in primary and secondary lung tumors. At present, few reports have explored the safety and efficacy of MWA for lung metastases from breast cancer.
METHODS
From January 2012 to January 2018, 32 breast cancer patients with 46 pulmonary metastases received CT-guided percutaneous MWA. The study was approved by the local institutional review board. The clinical efficacy and complications of MWA were investigated.
RESULTS
The median follow-up time was 32 months and the main effective rate was 97.8% (45/46). Five of 46 lesions had local progression (10.9%), with a median progression time of 10 months. The 1-, 3-, and 5-year overall survival (OS) rates were 96.9%, 53.3%, and 17.8%, respectively. The median OS time was 36 months. Among 46 MWA treatments, 11 (23.9%) had massive pneumothorax, two (4.3%) had massive pleural effusion, and two (4.3%) had a pulmonary infection.
CONCLUSION
CT-guided percutaneous MWA may be safe and effective for treating lung metastases from breast cancer.
背景
计算机断层扫描（CT）引导下经皮微波消融（MWA）是一种非常常见的消融方法，在原发性和继发性肺肿瘤中显示出良好的局部肿瘤控制率。目前，很少有报道探讨 MWA 治疗乳腺癌肺转移的安全性和疗效。
方法
本研究回顾性分析 2012 年 1 月至 2018 年 1 月期间 32 例乳腺癌患者 46 个肺转移病灶接受 CT 引导下经皮 MWA 的临床资料，所有患者均经病理证实，该研究经当地机构审查委员会批准。研究调查了 MWA 的临床疗效和并发症。
结果
中位随访时间为 32 个月，主要有效率为 97.8%（45/46）。46 个病灶中有 5 个（10.9%）出现局部进展，中位进展时间为 10 个月。1、3、5 年总生存率（OS）分别为 96.9%、53.3%和 17.8%，中位 OS 时间为 36 个月。在 46 次 MWA 治疗中，11 次（23.9%）出现大量气胸，2 次（4.3%）出现大量胸腔积液，2 次（4.3%）发生肺部感染。
结论
CT 引导下经皮 MWA 治疗乳腺癌肺转移可能是安全有效的。
Zotero 插件